Leiden University Medical Centre, Leiden, Netherlands.
BMJ. 2010 Dec 21;341:c7087. doi: 10.1136/bmj.c7087.
To compare the effect of induction of labour with a policy of expectant monitoring for intrauterine growth restriction near term.
Multicentre randomised equivalence trial (the Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)).
Eight academic and 44 non-academic hospitals in the Netherlands between November 2004 and November 2008.
Pregnant women who had a singleton pregnancy beyond 36+0 weeks' gestation with suspected intrauterine growth restriction.
Induction of labour or expectant monitoring.
The primary outcome was a composite measure of adverse neonatal outcome, defined as death before hospital discharge, five minute Apgar score of less than 7, umbilical artery pH of less than 7.05, or admission to the intensive care unit. Operative delivery (vaginal instrumental delivery or caesarean section) was a secondary outcome. Analysis was by intention to treat, with confidence intervals calculated for the differences in percentages or means.
321 pregnant women were randomly allocated to induction and 329 to expectant monitoring. Induction group infants were delivered 10 days earlier (mean difference -9.9 days, 95% CI -11.3 to -8.6) and weighed 130 g less (mean difference -130 g, 95% CI -188 g to -71 g) than babies in the expectant monitoring group. A total of 17 (5.3%) infants in the induction group experienced the composite adverse neonatal outcome, compared with 20 (6.1%) in the expectant monitoring group (difference -0.8%, 95% CI -4.3% to 3.2%). Caesarean sections were performed on 45 (14.0%) mothers in the induction group and 45 (13.7%) in the expectant monitoring group (difference 0.3%, 95% CI -5.0% to 5.6%).
In women with suspected intrauterine growth restriction at term, we found no important differences in adverse outcomes between induction of labour and expectant monitoring. Patients who are keen on non-intervention can safely choose expectant management with intensive maternal and fetal monitoring; however, it is rational to choose induction to prevent possible neonatal morbidity and stillbirth.
International Standard Randomised Controlled Trial number ISRCTN10363217.
比较经产妇临近足月时引产与期待监测治疗胎儿宫内生长受限的效果。
多中心随机等效试验(Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT))。
荷兰 8 所学术医院和 44 所非学术医院,2004 年 11 月至 2008 年 11 月。
妊娠 36+0 周以上、疑似胎儿宫内生长受限的单胎妊娠孕妇。
引产或期待监测。
主要结局是不良新生儿结局的综合指标,定义为出院前死亡、5 分钟 Apgar 评分<7、脐动脉 pH 值<7.05 或入住重症监护病房。剖宫产术(阴道器械分娩或剖宫产)为次要结局。分析采用意向治疗,置信区间计算为百分比或平均值的差异。
321 名孕妇被随机分配至引产组,329 名孕妇被分配至期待监测组。引产组婴儿的分娩时间提前了 10 天(平均差异-9.9 天,95%CI -11.3 至 -8.6),体重减轻了 130 克(平均差异-130 克,95%CI -188 克至-71 克)。引产组共有 17 名(5.3%)婴儿发生复合不良新生儿结局,而期待监测组有 20 名(6.1%)(差异-0.8%,95%CI -4.3%至 3.2%)。引产组有 45 名(14.0%)母亲行剖宫产术,期待监测组有 45 名(13.7%)(差异 0.3%,95%CI -5.0%至 5.6%)。
在足月疑似胎儿宫内生长受限的孕妇中,引产与期待监测在不良结局方面无显著差异。热衷于非干预治疗的患者可以安全地选择期待管理,并进行强化的母婴和胎儿监测;然而,为了预防可能的新生儿发病率和死产,选择引产是合理的。
国际标准随机对照试验编号 ISRCTN10363217。